Revenue and profit growth in the Pharmaceutical and Franchise Businesses
First written in FY2016-Q2. 18 of 35 entries say "Advanced", first in FY2016-Q3. Latest entry: 2026-10-13.
No other company in this theme has enough history to compare yet.
- 2026-10-13WorsenedEarnings
「In the pharmaceutical development ecosystem division, medium-molecule drug substance process development projects using the Molecular Hiving method expanded steadily, but sales and profit both remained sluggish because orders in the CMC field were limited.」
Although medium-molecule drug substance process development projects expanded, limited orders in the CMC field resulted in declines in both sales and operating income for the fine chemicals business as a whole. - FY2026-H1WorsenedAnnual report
「Accordingly, total business sales were ¥10,930 million, down 5.4% year on year, and operating income was ¥729 million, down 16.3%.」
The fine chemicals business posted lower sales and operating income year on year. The pharmaceutical ingredients platform performed well, but results were affected by limited CMC orders in the drug development ecosystem business and a decline in large projects in the pharmaceutical CDMO business. - 2026-04-13WorsenedEarnings
「As a result, total sales for this business were ¥5.125 billion, down 8.7% year on year, and operating income was ¥214 million, down 41.3%.」
The fine chemicals business reported year-on-year declines in sales and operating income, reversing the previous trend of increases in both sales and income. - FY2025-H1AdvancedAnnual report
「Accordingly, total business sales were ¥11,558 million, up 11.6% year on year, and operating income was ¥871 million, compared with an operating loss of ¥0 million in the year-earlier period.」
The fine chemicals business moved from an operating loss in the year-earlier period to operating income, while sales also increased 11.6%. - FY2024AdvancedAnnual report
「Accordingly, total business sales were ¥21,127 million, up 6.4% year on year, and operating income was ¥242 million, up 13.6%.」
Following the change in reportable segments, the fine chemicals business recorded sales of ¥21,127 million and operating income of ¥242 million, posting higher sales and operating income. - FY2024-Q2AdvancedAnnual report
「Accordingly, total business sales were ¥10,356 million, up 13.6% year on year, and operating income was ¥11 million, compared with an operating loss of ¥12 million in the year-earlier period.」
The fine chemicals business moved from an operating loss in the year-earlier period to operating income, while sales also increased 13.6%. - FY2024-Q1AdvancedAnnual report
「Accordingly, total business sales were ¥5,512 million, up 20.6% year on year, and operating income was ¥75 million, up 194.9%. Accordingly, total business sales were ¥2,399 million, up 21.1% year on year, and operating income was ¥182 million, compared with an operating loss of ¥9 million in the year-earlier period.」
Following the change in reportable segments, both the fine chemicals business and the pharmaceuticals business posted higher sales, and operating income also exceeded the year-earlier period. The pharmaceuticals business moved from an operating loss in the year-earlier period to profitability. - FY2023-Q3Revenue Growth and Profit DeclineAnnual report
「Accordingly, total business sales were ¥11,847 million, up 6.8% year on year, and operating income was ¥63 million, down 62.6%.」
The fine chemicals business posted a 6.8% year-on-year increase in sales, while operating income declined 62.6%. - FY2023-Q2WorsenedAnnual report
「Accordingly, total business sales were ¥7,254 million, down 3.7% year on year, and the business posted an operating loss of ¥83 million, compared with operating income of ¥473 million in the year-earlier period.」
The fine chemicals business posted lower sales and moved from operating income in the year-earlier period to an operating loss. - FY2023-Q1WorsenedAnnual report
「Accordingly, total business sales were ¥3,645 million, down 3.1% year on year, and the business posted an operating loss of ¥56 million, compared with operating income of ¥520 million in the year-earlier period.」
The fine chemicals business posted lower sales and moved from operating income in the year-earlier period to an operating loss. The pharmaceuticals business maintained higher sales, but operating income fell 53.2% year on year. - FY2022WorsenedAnnual report
「Accordingly, total business sales were ¥14,630 million, compared with ¥22,933 million in the year-earlier period, and operating income was ¥248 million, compared with operating income of ¥1,386 million.」
Following the segment reorganization, the fine chemicals business posted lower sales and operating income. The pharmaceuticals business also declined, recording sales of ¥11,754 million and operating income of ¥392 million, compared with ¥12,452 million and ¥908 million, respectively, in the previous year. - FY2022-Q3WorsenedAnnual report
「Accordingly, total business sales were ¥11,090 million, compared with ¥16,950 million in the year-earlier period, and operating income was ¥168 million, compared with operating income of ¥1,013 million.」
The fine chemicals business posted lower sales and operating income year on year, with operating income falling from ¥1,013 million to ¥168 million. - FY2022-Q2Lower sales and operating income in both fine chemicals and pharmaceuticalsAnnual report
「Accordingly, total business sales were ¥7,529 million, compared with ¥11,639 million in the year-earlier period, and operating income was ¥473 million, compared with operating income of ¥725 million. Accordingly, total business sales were ¥5,884 million, compared with ¥6,513 million in the year-earlier period, and operating income was ¥352 million, compared with operating income of ¥922 million.」
Both the fine chemicals business and the pharmaceuticals business posted lower sales and operating income year on year. Pharmaceutical ingredients remained firm in fine chemicals, while CDMO was sluggish. The pharmaceuticals business was affected by higher costs. - FY2022-Q1Fine chemicals profit up, pharmaceuticals profit downAnnual report
「Accordingly, total business sales were ¥3,763 million, compared with ¥5,316 million in the year-earlier period, and operating income was ¥520 million, compared with ¥203 million. Accordingly, total business sales were ¥2,746 million, compared with ¥3,174 million in the year-earlier period, and operating income was ¥156 million, compared with ¥625 million.」
Following the change in segments, the fine chemicals business posted lower sales but higher operating income, while the pharmaceuticals business posted lower sales and operating income. - FY2021-Q3AdvancedAnnual report
「Accordingly, total business sales were ¥16,950 million, up 10.5% year on year, and operating income was ¥1,015 million, up 19.4%. Accordingly, total business sales were ¥9,691 million, up 30.7% year on year, and operating income was ¥1,119 million, up 49.6%.」
Both the fine chemicals business and the pharmaceuticals business posted higher sales and operating income, with sales in the pharmaceuticals business up 30.7% and operating income up 49.6%. - FY2021-Q2AdvancedAnnual report
「Accordingly, total business sales were ¥11,639 million, up 18.1% year on year, and operating income was ¥726 million, up 54.5%. Accordingly, total business sales were ¥6,513 million, up 53.2% year on year, and operating income was ¥922 million, up 148.0%.」
Both the fine chemicals business and the pharmaceuticals business posted higher sales and operating income, with operating income in the pharmaceuticals business up 148.0% year on year. - FY2021-Q1Higher sales, divergent profit trends under the new segmentsAnnual report
「Accordingly, total business sales were ¥5,316 million, up 38.6% year on year, and operating income was ¥203 million, down 4.1%. Accordingly, total business sales were ¥3,174 million, up 54.5% year on year, and operating income was ¥625 million, up 288.1%.」
Following the change in segments, the fine chemicals business posted a substantial increase in sales but lower operating income, while the pharmaceuticals business posted higher sales and operating income. - FY2020Higher sales, divergent profit trends under the new segmentsAnnual report
「Accordingly, total business sales were ¥21,456 million, up 31.9% year on year, and operating income was ¥1,203 million, down 4.0%.」
The fine chemicals business posted a substantial increase in sales, owing in part to Spera Pharma's contribution to consolidated results, while operating income declined. The pharmaceuticals business recorded sales of ¥10,647 million and operating income of ¥998 million, both of which increased. - FY2020-Q2WorsenedAnnual report
「Accordingly, total business sales were ¥9,855 million, up 21.9% year on year, and operating income was ¥554 million, down 27.6%. Accordingly, total business sales were ¥4,252 million, up 7.8% year on year, and operating income was ¥372 million, down 18.8%.」
Following the change in reportable segments, both the fine chemicals business and the pharmaceuticals business posted higher sales, but operating income was below the year-earlier period. - FY2020-Q1ReframedAnnual report
「The former pharmaceuticals/FC business has been divided into the fine chemicals business, which primarily manufactures and sells pharmaceutical ingredients, and the pharmaceuticals business, which primarily manufactures and sells pharmaceuticals.」
The former pharmaceuticals/FC business was divided into the fine chemicals business and the pharmaceuticals business. Under the new classification, both the fine chemicals business and the pharmaceuticals business posted higher sales but lower operating income. - FY2019AdvancedAnnual report
「Accordingly, total business sales were ¥24,491 million, up 9.9% year on year, and operating income was ¥2,081 million, up 36.0%.」
The pharmaceuticals/FC business continued to post higher sales and operating income, with sales up 9.9% and operating income up 36.0%. - FY2019-Q3AdvancedAnnual report
「Accordingly, total business sales were ¥18,208 million, up 12.4% year on year, and operating income was ¥1,729 million, up 46.9%.」
The Pharmaceuticals and FC business recorded higher revenue and profit for the cumulative third quarter, with both revenue and operating profit exceeding the year-earlier levels. - FY2019-Q2AdvancedAnnual report
「Accordingly, total business sales were ¥12,029 million, up 13.4% year on year, and operating income was ¥1,226 million, up 59.3%.」
The pharmaceuticals/FC business posted higher sales and operating income for the six months ended Q2, with both sales and operating income exceeding the year-earlier period. - FY2019-Q1AdvancedAnnual report
「Accordingly, total business sales were ¥5,442 million, up 12.9% year on year, and operating income was ¥455 million, up 185.3%.」
The pharmaceuticals/FC business posted higher sales and operating income, with operating income up 185.3% year on year. - FY2018AdvancedAnnual report
「Accordingly, total business sales were ¥22,281 million, up 3.5% year on year, and operating income was ¥1,530 million, up 7.4%.」
The pharmaceuticals/FC business posted higher sales and operating income for the full year, recording sales of ¥22,281 million and operating income of ¥1,530 million. - FY2018-Q3AdvancedAnnual report
「Accordingly, total business sales were ¥16,194 million, up 1.2% year on year, and operating income was ¥1,177 million, up 1.5%.」
The pharmaceuticals/FC business posted higher sales and operating income for the nine months ended Q3, recording sales of ¥16,194 million and operating income of ¥1,177 million. - FY2018-Q2WorsenedAnnual report
「Accordingly, total business sales were ¥10,607 million, up 0.3% year on year, and operating income was ¥769 million, down 3.9%.」
The pharmaceuticals/FC business posted a slight increase in sales, while operating income fell 3.9% year on year. - FY2018-Q1WorsenedAnnual report
「Accordingly, total business sales were ¥4,822 million, down 1.4% year on year, and operating income was ¥159 million, down 50.2%.」
The pharmaceuticals/FC business posted lower sales, while operating income also fell 50.2% year on year. - FY2017AdvancedAnnual report
「Accordingly, total business sales were ¥21,519 million, up 0.9% year on year, and operating income was ¥1,425 million, up 10.3%.」
The pharmaceuticals/FC business posted higher sales and operating income for the full year, recording sales of ¥21,519 million and operating income of ¥1,425 million. - FY2017-Q3AdvancedAnnual report
「Accordingly, total business sales were ¥16,007 million, up 1.7% year on year, and operating income was ¥1,160 million, up 20.8%.」
The pharmaceuticals/FC business posted higher sales and operating income, with operating income up 20.8% year on year. - FY2017-Q2AdvancedAnnual report
「As a result, total revenue for the business was ¥10.574 billion, up 3.3% year on year, and operating profit was ¥800 million, up 30.5%.」
The Pharmaceuticals and FC business recorded higher revenue and profit for the cumulative second quarter, with operating profit up 30.5% year on year. - FY2017-Q1AdvancedAnnual report
「As a result, total revenue for the business was ¥4.89 billion, up 2.5% year on year, and operating profit was ¥320 million, up 16.1%.」
The Pharmaceuticals and FC business recorded higher revenue and profit in the first quarter, and the growth rates for revenue and operating profit were disclosed. - FY2016AdvancedAnnual report
「Total revenue for the business was ¥21.328 billion, up 9.8% from the previous consolidated fiscal year, and operating profit was ¥1.292 billion, up 39.7%.」
The Pharmaceuticals and FC business recorded higher revenue and profit for the full fiscal year, and the growth rates for revenue and operating profit were also disclosed. - FY2016-Q3AdvancedAnnual report
「As a result, total revenue for the business was ¥15.735 billion, up 10.4% year on year, and operating profit was ¥960 million, up 25.7%.」
The Pharmaceuticals and FC business recorded higher revenue and profit for the cumulative third quarter, with both revenue and operating profit exceeding the year-earlier levels. - FY2016-Q2First statedAnnual report
「As a result, total revenue for the business was ¥10.234 billion, up 9.1% year on year, and operating profit was ¥613 million, up 20.4%.」
The Pharmaceuticals and FC business recorded year-on-year increases in both revenue and operating profit.